CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcoming investor conferences in November and December:

Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine’s proprietary targeted LNP in a key step to developing a novel in vivo treatment for sickle cell disease and beta thalassemia

CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio, today announced that they have entered into a collaboration and nonexclusive license agreement to combine Editas Medicine’s CRISPR Cas12a genome editing systems with Genevant’s proprietary LNP technology in the development of in vivo gene editing medicines directed to two undisclosed targets in Editas’ upregulation strategy.

Webinar to be held on Tuesday, October 22, at 8:00 a.m. ET

Strengthens balance sheet with non-dilutive capital to enable further pipeline development and related strategic priorities

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcoming investor conferences to discuss the Company and its programs, including reni-cel:

On track to present additional clinical data from the RUBY trial and the EdiTHAL trial by year-end

All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusion

All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni-cel) infusion

CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizgamglogene autogedtemcel (reni-cel) have been accepted for presentation at the European Hematology Association (EHA) Hybrid Congress being held June 13-16, 2024, in Madrid, Spain, and via livestream.